Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting

Highlights from the Data Presentation Initial safety data presented on the first 10 chronically HBV-infected patients representing 674 patient days of treatment VRON-0200 was well tolerated, with no serious adverse events (SAEs) observed: no patients discontinued treatment one treatment…